BDSX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.84M

+21.59%

-0.942

-21.5%

23.17M

+29%

-0.760

-52.5%

25.33M

+26.55%

-0.633

-60.42%

Estimates Revision

The market is revising Upward the revenue expectations for Biodesix, Inc. (BDSX) for FY2025, with the revenue forecasts being adjusted by 1.86% over the past three months. During the same period, the stock price has changed by -3.42%.

Revenue Estimates for FY2025

Revise Upward

+1.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.66%

In Past 3 Month

Stock Price

Go Down

-3.42%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 7.340

Low

20.00

Averages

30.00

High

40.00

Current: 7.340

Low

20.00

Averages

30.00

High

40.00

Canaccord

Buy

downgrade

$30 -> $20

2025-09-19

Reason

Canaccord

Price Target

$30 -> $20

2025-09-19

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Biodesix to $20 from $30 and keeps a Buy rating on the shares. The firm updated its model to reflect its 20-for-1 reverse split which reduces the amount of outstanding shares to 8 million from 156 million. Importantly, the company appears to have an at-the-market facility it could leverage to help it maintain operations through potentially cash flow breakeven/profitability.

Scotiabank

Outperform

NULL

downgrade

$3 -> $2

2025-05-21

Reason

Scotiabank

Price Target

$3 -> $2

2025-05-21

downgrade

Outperform

NULL

Reason

Scotiabank lowered the firm's price target on Biodesix to $2 from $3 and keeps an Outperform rating on the shares. The company's Q1 revenue miss and FY25 revenue guidance reduction can be attributed to the shift in the company's commercial strategy, the analyst tells investors. The firm continues to believe the market for lung nodule risk assessment is a multi-billion-dollar opportunity that is under-penetrated and the company faces minimal competition.

William Blair

Outperform -> Market Perform

downgrade

2025-05-14

Reason

William Blair

Price Target

2025-05-14

downgrade

Outperform -> Market Perform

Reason

Canaccord

Kyle Mikson

Buy

downgrade

2025-05-14

Reason

Canaccord

Kyle Mikson

Price Target

2025-05-14

downgrade

Buy

Reason

Canaccord analyst Kyle Mikson lowered the firm's price target on Biodesix to $1.50 from $2.50 and keeps a Buy rating on the shares. The firm said the target decrease is driven by lower near- and long-term revenue estimates after the company posted Q1 results that were below expectations.

TD Cowen

Buy

downgrade

$3 -> $2

2025-05-14

Reason

TD Cowen

Price Target

$3 -> $2

2025-05-14

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Biodesix to $2 from $3 and keeps a Buy rating on the shares. The firm updated its model as sales force issues were a drag on 1Q results and the guide down.

Craig-Hallum

Buy

downgrade

2025-05-14

Reason

Craig-Hallum

Price Target

2025-05-14

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Biodesix to $1.50 from $3 and keeps a Buy rating on the shares. The firm believes Biodesix is likely to sell off even further on a Q1 volume and revenue miss and lowered guidance. The company cites disruption from a sales force reorganization. Craig-Hallum expects it will take a few quarters for the company to get back on the right track, and thus has revised its estimates below the low end of the new guidance range.

Valuation Metrics

The current forward P/E ratio for Biodesix Inc (BDSX.O) is -2.73, compared to its 5-year average forward P/E of -4.55. For a more detailed relative valuation and DCF analysis to assess Biodesix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.55

Current PE

-2.73

Overvalued PE

-0.38

Undervalued PE

-8.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.10

Current EV/EBITDA

-9.94

Overvalued EV/EBITDA

-1.80

Undervalued EV/EBITDA

-16.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.14

Current PS

0.62

Overvalued PS

5.88

Undervalued PS

0.40

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1991.2% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BDSX News & Events

Events Timeline

No data

News

9.5

11-04NASDAQ.COM

Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

4.5

10-31TipRanks

Daily Update on VTI ETF for October 31, 2025

4.5

10-30TipRanks

Daily Update on VTI ETF for October 30, 2025

People Also Watch

Frequently Asked Questions

What is Biodesix Inc (BDSX) stock price today?

The current price of BDSX is 7.34 USD — it has decreased -6.5 % in the last trading day.

What is Biodesix Inc (BDSX)'s business?

Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.

What is the price predicton of BDSX Stock?

What is Biodesix Inc (BDSX)'s revenue for the last quarter?

Biodesix Inc revenue for the last quarter amounts to 21.77M USD, increased 19.93 % YoY.

What is Biodesix Inc (BDSX)'s earnings per share (EPS) for the last quarter?

Biodesix Inc. EPS for the last quarter amounts to -1.16 USD, decreased -17.14 % YoY.

What changes have occurred in the market's expectations for Biodesix Inc (BDSX)'s fundamentals?

How many employees does Biodesix Inc (BDSX). have?

Biodesix Inc (BDSX) has 273 emplpoyees as of December 15 2025.

What is Biodesix Inc (BDSX) market cap?

Today BDSX has the market capitalization of 62.45M USD.